<DOC>
	<DOC>NCT02618941</DOC>
	<brief_summary>This is a follow-up study to assess safety and clinical activity of continued AFFITOPE速 PD01A vaccinations in patients with Parkinson's disease. Patients, who have already participated in the AFF008 program will be involved and will receive a second boost immunization with AFFITOPE速 PD01A. One study site in Vienna (Austria) will be involved. In addition, up to 6 patients will be offered participation within an untreated control Group.</brief_summary>
	<brief_title>Follow-up Study to Assess a Second Boost Immunization With AFFITOPE速 PD01A With Regard to Safety and Clinical Activity (AFF008AA)</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Prior participation in AFF008, AFF008E and AFF008A Written informed consent signed and dated by the patient and, preferentially, the caregiver In the investigator's opinion, does not have visual or auditory impairments that would reduce the patients' ability to complete study questionnaires or be unable to receive instructions for These Female patients of childbearing potential are eligible if they use a medically accepted contraceptive method All changes in conventional PD therapies must be available to the sponsor; in particular pharmacologic symptomatic PD medication allowing transformation to a Levodopa standard dose A potential participant should be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except PD therapies, these will be recorded separately) for at least 30 days prior to Visit 1 if considered relevant by the investigator Women of childbearing potential without birth control or pregnant women Participation in another clinical trial within 3 months before Visit 1 (except AFF008A) History of questionable compliance to visit schedule; patients not expected to complete the clinical trial Autoimmune disease or allergy to components of the vaccine History of cancer (Exceptions: nonmelanoma skin cancer, intraepithelial cervical neoplasia) Active infectious disease (e.g., Hepatitis B, C) Immunodeficiency Significant systemic illness Alcoholism or substance abuse Prior and/or current treatment with experimental immunotherapeutics including IVIG with the exception of AFFITOPE速 PD01A, with immune modulating drugs or treatment with deep brain stimulation Venous status rendering it impossible to place an i.v. access</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>